Homepage

Our Purpose and Ambition

We are a global leader in generic and biosimilar pharmaceuticals, committed to driving access to medicine
Read More

COVID-19 Information Center

The information center provides a central hub for news, guidance and resources.
Read More

Explore Novartis

About Us
Who We Are
Our Work
What We Do
Careers
Job Search

Recent Updates

Media Release / Jul 25

Applications for proposed first-of-a-kind multiple sclerosis biosimilar natalizumab accepted by US FDA and EMA

Read More
Media Release / Jul 21

Sandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyrimoz® (adalimumab-adaz) high concentration formulation (HCF)

Read More
Media Release / Jul 19

Novartis delivers continued strong momentum of key growth brands, progress on strategic initiatives and confirms FY’22 Group guidance

Read More
Media Release / Jun 17

Sandoz Application for proposed biosimilar adalimumab’s high concentration formulation accepted by EMA

Read More
View All
NEWS: Sandoz scientists, together with external researchers, publish first systematic review on biosimilar-to-biosi… https://t.co/NInrARQ5jv 3 days 17 hours ago

Our Work

At Sandoz, we discover new ways to improve and extend people’s lives. We pioneer novel approaches to help people around the world access high-quality medicine.

Learn More